Abstract:

Study aimed at determining prevalence of Multi Drug Resistance Tuberculosis at Ndola Central Hospital among Adults, Ndola, Zambia.

A retrospective cohort study review was conducted among adult MDR-TB patients at Ndola Central Hospital from 15^th August to 22^nd August 2014. All records for MDR TB patients from MDR TB ward were reviewed (January 2010 up to June 2014). Sample size was 114, Convenient sampling was done using MDR- TB treatment register and laboratory results. Data was analyzed using Epi Data version 3, and Pearson Chi square. The findings revealed that 48.2% of the patients with MDR TB had sputum positive results for culture, compared to 6.6% whose sputum was negative. The study also found that, of all (114) MDR TB patients who were admitted in MDR TB ward at Ndola Central Hospital, only 44% had Multi drug resistance , 33% had Mono resistance, while 22.6% had Poly resistance. The findings revealed that 29.8% were new cases, 23.7% treatment failure, and 4.9% relapse. Discussion of findings shows that; almost 50% of the respondents had MDR TB which was confirmed by sputum culture results and others had poly resistance and mono resistance. The respondents were either new cases, treatment failure or relapse cases, which showed that there could be other factors associated with drug resistance.

Conclusion: prevalence rate of MDR TB was 44% and is major threat for TB control measures and proper treatment options.

Keywords: Prevalence, MDR-TB Resistance, Ndola, Zambia.

References:

[1]. WHO (2014): Global Tuberculosis Report 2014. WHO Library Cataloguing-in-Publication Data. ISBN 978 92 4 156480 9

[2]. Dalton Dr Tracy Dalton, Peter Cegielski, MD,Somsak Akksilp, MD, Luis Asencios, MPH, Janice Campos Caoili, MD, Prof Sang-Nae Cho, PhD, Vladislav V Erokhin, MD, Julia Ershova, PhD, Ma Tarcela Gler, MD, Boris Y Kazennyy, MD, Hee Jin Kim, MD, Kai Kliiman, MD, Ekaterina Kurbatova, MD, Charlotte Kvasnovsky, MD, Vaira Leimane, MD, Martie van der Walt, PhD, Laura E Via, PhD, Grigory V Volchenkov, MD, Martin A Yagui, MD, Hyungseok Kang, MD, (2012) The Global PETTS ; 1406-17; “prevalence of and risk factors for resistance to second line drugs in people with multi drug resistance tuberculosis in eight countries. A prospective cohort study” the Lancet 380(9851)

[3]. Scientific Facts on drug resistance Tuberculosis (http:// www.greenfacts.org/en/tuberculosis/1-2-mdr-tb-xdr.htm)

[4]. Farmer Paul (2001) “The major infectious diseases in the world- to treat or not to treat?” New England journal of medicine 345 (3): 208-10.

[5]. Blower SM, Chao T, Modeling the emergency of the ‘hot zones’: Tuberculosis and amplification dynamics of the drug dynamics of drug resistance. Nat med 2004 ;10 (10): 1111-6

[6]. Mirsaedi SM, Tabasi P, Khoshnood K, Pooramir, M V, Rowhani- Rahbar A, Mansoori S D (2005); Treatment of multiple drug resistance tuberculosis MDR – TB in Iran. Int/ infect dis 2005;9;(6):317-22

[7]. CDC June 1992/ 41(RR-11); 59-71 management of persons exposed to multidrug resistant tuberculosis. Recommendations and reports.

[8]. WHO multi drug and extensively drug resistant to Tb (m/xdr-Tb): 2010 Global report on surveillance and response 2010.

[9]. Nathason Eva Eva Nathanson, M.Sc., Paul Nunn, F.R.C.P., Mukund Uplekar, M.D., Katherine Floyd, Ph.D., Ernesto Jaramillo, M.D., Ph.D., Knut Lönnroth, M.D., Ph.D., Diana Weil, M.Sc., and Mario Raviglione, M.D. 2010 MDR Tuberculosis- critical steps for prevention and control. N Engl J Med 2010; 363:1050-1058September 9, 2010DOI: 10.1056/NEJMra0908076

http://heraf.or.ke/Africa/xdr-and-mdr-tb-in-kenya.html

[10]. Weyner Karin 2003 MDR-TB in South Africa: New Strategies and policies, MCR Unit for Tb operational and policy Research. Pretoria.

[11]. MOH : The National TB/Leprosy Control Programme; Guidelines for the Programmatic Management of Drugs- Resistant Tuberculosis, Draft Copy.

[12]. Kapata N., Chanda-Kapata P, Bates M, Mwaba P, Cobelens F, Grobusch MP, Zumla A. (2013) Multi Drug Resistant TB in Zambia: a review of national data from 2001 to 2011.

[13]. Ndola Central Hospital: MDR TB WARD;HMIS 2009 TO 2014 : CASES of MDR TB admitted

[14]. Surveillance and DOTs Implementation in Zambia; 2006 Data.

[15]. Fantahun Biadglegne1,2,3,4*, Ulrich Sack3,4 and Arne C Rodloff (2014): Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and care http://www.aricjournal.com/content/3/1/3. Retrieved on 28/11/15.

[16]. World Health Organization(2013): Global Tuberculosis control. Geneva: World Health Organization; 2013. (http://www.who.int/tb/data).